(Q51552355)

6 April 2018

title

Troglitazone prevents fatty changes of the liver in obese diabetic rats. (English)

1 reference

6 April 2018

0 references

Jia DM

1

1 reference

6 April 2018

Tabaru A

2

1 reference

6 April 2018

Akiyama T

3

1 reference

6 April 2018

Abe S

4

1 reference

6 April 2018

Otsuki M

5

1 reference

6 April 2018

publication date

1 October 2000

1 reference

6 April 2018

Journal of Gastroenterology and Hepatology

published in

1 reference

6 April 2018

volume

15

1 reference

6 April 2018

issue

10

1 reference

6 April 2018

page(s)

1183-1191

1 reference

6 April 2018

Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02316.X

Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02316.X

Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02316.X

Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02316.X

Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02316.X

Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02316.X

Troglitazone: a review of its use in the management of type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02316.X

Troglitazone-induced hepatic failure leading to liver transplantation. A case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02316.X

An autopsy case of troglitazone-induced fulminant hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02316.X

Sulfated glycans stimulate endocytosis of the cellular isoform of the prion protein, PrPC, in cultured cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02316.X

Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02316.X

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02316.X

Expression of the peroxisome proliferator-activated receptor (PPAR) in the mouse colonic mucosa

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02316.X

The organization, promoter analysis, and expression of the human PPARgamma gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02316.X

Tissue distribution and quantification of the expression of mRNAs of peroxisome proliferator-activated receptors and liver X receptor-alpha in humans: no alteration in adipose tissue of obese and NIDDM patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02316.X

The nuclear eicosanoid receptor, PPARgamma, is aberrantly expressed in colonic cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02316.X

Peroxisome proliferator-activated receptor gamma induces growth arrest and differentiation markers of human colon cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02316.X

Activators of the nuclear receptor PPARgamma enhance colon polyp formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02316.X

Spontaneous long-term hyperglycemic rat with diabetic complications. Otsuka Long-Evans Tokushima Fatty (OLETF) strain

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02316.X

Effects of obesity and inheritance on the development of non-insulin-dependent diabetes mellitus in Otsuka-Long-Evans-Tokushima fatty rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02316.X

Which is the primary etiologic event in Otsuka Long-Evans Tokushima Fatty rats, a model of spontaneous non-insulin-dependent diabetes mellitus, insulin resistance, or impaired insulin secretion?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02316.X

Metabolic abnormalities in the genetically obese and diabetic Otsuka Long-Evans Tokushima Fatty rat can be prevented and reversed by alpha-glucosidase inhibitor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02316.X

Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02316.X

Regulation of PPAR gamma gene expression by nutrition and obesity in rodents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02316.X

The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of ApcMin-induced intestinal neoplasia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2000.02316.X

10.1046/J.1440-1746.2000.02316.X

21 January 2018

Identifiers

DOI

1 reference

6 April 2018

1 reference

6 April 2018